The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease
Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness t...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/7/3956 |
| _version_ | 1797438905696387072 |
|---|---|
| author | Eitan Giat Ilan Ben-Zvi Merav Lidar Avi Livneh |
| author_facet | Eitan Giat Ilan Ben-Zvi Merav Lidar Avi Livneh |
| author_sort | Eitan Giat |
| collection | DOAJ |
| description | Familial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness to colchicine, the cornerstone of FMF treatment, is nowadays addressed by IL-1- blockers. Each of the two IL-1 blockers currently used in FMF, anakinra and canakinumab, has its own merits for FMF care. Here we focus on anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, and explore the literature by using PubMed regarding the utility of anakinra in certain conditions of FMF. Occasionally we enrich published data with our own experience. To facilitate insights to anakinra role, the paper briefs some clinical, genetic, pathogenetic, and management aspects of FMF. The clinical settings of FMF covered in this review include colchicine resistance, AA amyloidosis, renal transplantation, protracted febrile myalgia, on- demand use, leg pain, arthritis, temporary suspension of colchicine, pediatric patients, and pregnancy and lactation. In many of these instances, either because of safety concerns or a necessity for only transient and short-term use, anakinra, due to its short half-life, is the preferred IL-1 blocker. |
| first_indexed | 2024-03-09T11:44:05Z |
| format | Article |
| id | doaj.art-002c606f75914f1080fa2a5380f93032 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T11:44:05Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-002c606f75914f1080fa2a5380f930322023-11-30T23:24:32ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-04-01237395610.3390/ijms23073956The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the DiseaseEitan Giat0Ilan Ben-Zvi1Merav Lidar2Avi Livneh3FMF Clinic, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan 5265601, IsraelFMF Clinic, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan 5265601, IsraelFMF Clinic, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan 5265601, IsraelFMF Clinic, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan 5265601, IsraelFamilial Mediterranean fever (FMF), the most frequent monogenic autoinflammatory disease, is manifested with recurrent and chronic inflammation and amyloid A (AA) amyloidosis, driven by overproduction of interleukin 1 (IL-1) through an activated pyrin inflammasome. Consequently, non-responsiveness to colchicine, the cornerstone of FMF treatment, is nowadays addressed by IL-1- blockers. Each of the two IL-1 blockers currently used in FMF, anakinra and canakinumab, has its own merits for FMF care. Here we focus on anakinra, a recombinant form of the naturally occurring IL-1 receptor antagonist, and explore the literature by using PubMed regarding the utility of anakinra in certain conditions of FMF. Occasionally we enrich published data with our own experience. To facilitate insights to anakinra role, the paper briefs some clinical, genetic, pathogenetic, and management aspects of FMF. The clinical settings of FMF covered in this review include colchicine resistance, AA amyloidosis, renal transplantation, protracted febrile myalgia, on- demand use, leg pain, arthritis, temporary suspension of colchicine, pediatric patients, and pregnancy and lactation. In many of these instances, either because of safety concerns or a necessity for only transient and short-term use, anakinra, due to its short half-life, is the preferred IL-1 blocker.https://www.mdpi.com/1422-0067/23/7/3956familial Mediterranean fever (FMF)anakinrainterleukin 1 blockerscolchicine failureAA amyloidosisexertional leg pain |
| spellingShingle | Eitan Giat Ilan Ben-Zvi Merav Lidar Avi Livneh The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease International Journal of Molecular Sciences familial Mediterranean fever (FMF) anakinra interleukin 1 blockers colchicine failure AA amyloidosis exertional leg pain |
| title | The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease |
| title_full | The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease |
| title_fullStr | The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease |
| title_full_unstemmed | The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease |
| title_short | The Preferential Use of Anakinra in Various Settings of FMF: A Review Applied to an Updated Treatment-Related Perspective of the Disease |
| title_sort | preferential use of anakinra in various settings of fmf a review applied to an updated treatment related perspective of the disease |
| topic | familial Mediterranean fever (FMF) anakinra interleukin 1 blockers colchicine failure AA amyloidosis exertional leg pain |
| url | https://www.mdpi.com/1422-0067/23/7/3956 |
| work_keys_str_mv | AT eitangiat thepreferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT ilanbenzvi thepreferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT meravlidar thepreferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT avilivneh thepreferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT eitangiat preferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT ilanbenzvi preferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT meravlidar preferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease AT avilivneh preferentialuseofanakinrainvarioussettingsoffmfareviewappliedtoanupdatedtreatmentrelatedperspectiveofthedisease |